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Abstract 
Nuclear size normally scales with the size of the cell, but in cancer this "karyoplasmic 
ratio" is disrupted. This is particularly so in more metastatic tumors where changes in the 
karyoplasmic ratio are used in both diagnosis and prognosis for several tumor types. 
However, the direction of nuclear size changes differs for particular tumor types: for 
example in breast cancer larger nuclear size correlates with increased metastasis while for 
lung cancer smaller nuclear size correlates with increased metastasis. Thus there must be 
tissue-specific drivers of the nuclear size changes, but proteins thus far linked to nuclear 
size regulation are widely expressed. Notably, for these tumor types ploidy changes have 
been excluded as the basis for nuclear size changes and so the increased metastasis is 
more likely to have a basis in the nuclear morphology change itself. We review what is 
known about nuclear size regulation and postulate how such nuclear size changes can 
increase metastasis and why the directionality can differ for particular tumor types. 
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Introduction  
Breaking the microscope's 1 µm resolution barrier in the mid-1800s revealed phenotypic 
and morphological changes in cell nuclei during cancer progression. An early description 
of these changes published in 1860 by Lionel S. Beale (King’s College London) reported 
alteration of nuclear size and shape in the sputum of a patient with cancer of the pharynx 
(1). Eighty years later George Papanicolaou developed a stain to visualize cytoplasmic 
and nuclear structural features for the diagnosis/staging of cervical cancer, setting a 
standard tool still used today. Though subsequent advances added many other nuclear 
features to fine-tune diagnoses such as chromatin organization and numbers and sizes of 
nucleoli, the nuclear size and shape changes are the most microscopically evident 
characteristics in tumor progression and are highly characteristic for a given tumor type; 
hence, size is used prognostically for stage and progression of each tumor type (2). It is 
notable that in many tumor types where nuclear size is used prognostically the size 
changes have been shown to be independent of ploidy changes (3). Changes in ploidy 
greatly expand the number of indirect mechanisms that could lead to increased metastasis 
that would include increasing the burden of proper mitotic segregation. In this short review/ 
hypothesis paper we will only focus on the types of cancer where ploidy has been 
excluded as a factor in nuclear size changes and thus where the size change itself is more 
likely to contribute to the increase in metastatic potential. Determining the function and 
mechanism of these nuclear size changes in cancer, is nonetheless made complicated 
because they tend to be tissue-specific in degree and direction — e.g. smaller nuclei 
indicate increased metastasis in osteosarcoma and lung carcinoma (4,5) while larger 
nuclei indicate increased metastasis in breast, prostate, liver, ovarian, pancreatic and 
colorectal cancers and small-cell cervical, epidermal squamous, papillary thyroid and 
urinary bladder carcinomas (6–15). 
 Nuclear size varies in different cell types and through differentiation, but the 
karyoplasmic ratio — of nucleoplasmic to cytoplasmic volume — is generally maintained 
for most cell types. Thus, nuclear size generally scales with cell size (16). The 
karyoplasmic ratio is maintained during the cell cycle (17,18) during which the nucleus 
typically increases several fold in volume and a general mechanism for this size scaling is 
conserved to yeast (19,20). This scaling of the karyoplasmic ratio has broken in more 
metastatic cancer cells, raising the question whether the scaling disruption or the nuclear 
size change itself contributes an advantage to the tumor? With the many functions now 
known for the nuclear envelope (NE), advantages could range from changes in gene 
regulation/signaling to mechanical nuclear aspects enabling faster migration or the easier 
squeezing through cell junctions to invade different tissues. 
 
Possible mechanisms of nuclear size regulation through the NE  
The NE is comprised of outer (ONM) and inner (INM) nuclear membranes and associated 
proteins (21,22). The membranes are separated by a lumen and connected where nuclear 
pore complexes (NPCs), comprised of ~30 core proteins, are inserted (23,24). NPCs 
contain only three transmembrane proteins, but there are hundreds of other Nuclear 
Envelope Transmembrane proteins (NETs) in both membranes (25–28). Functions of 
ONM NETs are just beginning to be discovered, but many connect to cytoplasmic 
filaments (27,29–32) while others function in cell cycle regulation (33–35). Thus far many 
INM NETs characterized make connections important for genome organization, gene 
regulation, and signalling (36–43). INM NETs also connect to a polymer of the type V 
intermediate filament nuclear lamins that confers structural stability to the nucleus 
(22,29,44). The NE disassembles in mitosis of higher eukaryotes and the reassembled 
daughter nuclei are much smaller. This is because at the end of S-phase the genome has 
doubled to 4N, the chromatin is decondensed and the nucleus is filled with proteins and 
RNA whereas the reforming NE surrounds a 2N genome that is highly condensed. In 
general the nucleus volume increases around 2 fold through the cell cycle (45). 
 As the NE is the outer shell that delimits the nucleus, many NE proteins could be 
limiting for nuclear size. These range from NPC transport functions to the lamin scaffolding 
to the connections to cytoplasmic filaments or proteins involved in lipid synthesis. Such 
proteins could be under a feedback regulatory mechanism for amounts synthesized or a 
timed mechanism that links nuclear size increases during the cell cycle to the length of a 
particular stage. Thus changes to gene expression and cell proliferation in cancer cells 
might underlie nuclear size changes. Notably, such changes in gene expression could 
themselves be influenced by nuclear size changes if this alters the relative amount of 
peripheral heterochromatin and gene silencing (Fig. 1A).  
 It is also possible that a completely independent sensor mechanism maintains the 
karyoplasmic ratio, for example sensing a change in tension between chromatin contacts 
and the NE on one side and connections with cytoplasmic filaments on the other. If this 
were the case then changes in cancer cells to NE-chromatin or NE-cytoplasmic filament 
interactions might underlie nuclear size changes. Such changes could also explain nuclear 
shape changes and NE blebbing that often accompanies the size changes in cancer cells 
(Fig.1B). 
 A third mechanism might involve post-translational modifications, particularly 
phosphorylation cascades that often go awry in cancer cells. Such modifications are 
important for both the stability of the lamin polymer and for NE-chromatin interactions. 
Indeed, mitotic disassembly of the lamin polymer is coupled with hyperphosphorylation of 
both lamins and NETs to break the interactions between them and their interactions with 
chromatin (Fig. 1C). 
 
Factors found to regulate nuclear size 
Lamins  
Lamins are good candidates to regulate nuclear size as they form an intermediate filament 
polymer, the nuclear lamina, that provides the main mechanical stability to the nucleus 
(46–48). Moreover, lamins are also the most abundant NE proteins at ~9 million copies per 
mammalian cell nucleus (49). Thus their limitation might be predicted to restrict nuclear 
growth. Accordingly, lamins influence nuclear size in Xenopus laevis embryos in a manner 
that depends on import of lamin B3 and this lamin is reported to be required for NE growth 
during egg development (50). Both Xenopus and mammalian studies have concluded that 
lamins are essential for nuclear scaling during interphase and their limitation leads to 
failure in nuclear growth (51–53). Notably, from the standpoint of a limiting function, 
several NPC proteins have also been linked to cancer and nuclear size regulation (54). 
Lamins could also contribute to nuclear shape changes in cancer cells as their loss or 
mutation in several heritable diseases yields defects in nuclear morphology (55,56). 
 Despite these results, it is unlikely that, apart from being limiting for growth, lamins 
could control nuclear size on their own as both the total amount of lamin protein and the 
relative amounts of different lamin subtypes in the nuclear lamina change during 
development (57–59). A-type lamins, encoded by the LMNA gene, are present in the 
earliest embryonic stages from maternal protein, but new protein is not expressed at these 
stages so that it disappears for most embryonic stages and reappears later in tissue 
differentiation (60,61).  
 The change in lamina constitution in development is interesting in light of changes 
observed in lamina constitution in some cancer types. The general tendency observed is 
that B-type lamins continue to be expressed in tumors while A-type lamins are down-
regulated (62–64). Because A-type lamins appear later in development, this led to the idea 
that their loss reflects retro-differentiation or de-differentiation and so might drive or at least 
reflect the return to a more proliferative and undifferentiated state (65). However, research 
in this direction was dropped when it was observed that for some cancer types such as 
colorectal cancer the more metastatic tumors had increased A-type lamin levels (66). 
Though at the time this appeared to kill the retro-/de-differentiation theory, subsequent 
work found that in colonic crypt epithelia the earliest progenitor cell lineages at the base of 
the crypts in fact express lamin A and this disappears as cells differentiate and migrate up 
the sides of the crypt. Then in the more differentiated cells at the top of the crypts lamin A 
becomes expressed again (66). Thus, the less differentiated more proliferative cell likely 
gives rise to the more metastatic tumor. This study additionally revealed a potential 
mechanism for lamin A in metastasis: that lamin A functions inside the nucleus can 
influence the expression of genes encoding proteins that contribute to actin bundling and 
dynamics such as they showed for T-plastin (66). The effects on actin dynamics could 
explain how a lamin A-expressing tumor could lead to metastasis and tumor spread as cell 
mobility would be increased and, indeed, other studies with lamin A knockout cells found 
that in the absence of lamin A cells migrated into a scratch wound more slowly (47,67). 
Interestingly, while this beautifully explains how lamin A-expressing tumors can be more 
metastatic, it leaves us even more in the dark to understand the contribution of loss of 
lamin A in most cancer types to tumorigenesis.  
 
Perinuclear structures  
 Connections between the nucleus and the cytoskeleton contribute to both the 
overall mechanical stability of the cell and its migratory capacity (46–48). Such 
connections could in theory — particularly in context of the principles of tensegrity (68,69) 
— enable all major cytoplasmic filament systems to contribute to nuclear size regulation 
and impact on cell migration as actin microfilaments, microtubules and intermediate 
filaments all connect to the NE (27,30,70). One recent report identified formins, an actin 
nucleating family, as players in nuclear protection during confined migration: when formins 
were knocked down nuclei tended to rupture more when migrating through confined 
channels compared to wild-type cells (71). This kind of function, however, cannot account 
for tissue specific phenotypes found in different cancer types. In contrast, the proteins that 
connect the nucleoskeleton to the cytoskeleton have been directly linked to nuclear size 
regulation and some NETs that contribute to such connecting complexes are tissue-
specific. The core proteins involved in this connection are SUN-domain containing proteins 
of the INM and KASH-domain containing proteins of the ONM. Together these form the 
Linker of Nucleoskeleton and Cytoskeleton (LINC) complex (29) that also supports 
mechanosignal transduction to the nucleus (67,72). SYNE/nesprins are a family of KASH-
domain containing proteins and disruption of LINC using a dominant-negative nesprin 
mutant leads to nuclear size defects (73). Moreover two nesprins in particular, Nesprin-2 
and Nesprin-3, are proposed to form a cytoplasmic cage around the nucleus to contribute 
to its mechanical support (73). As for lamins, nesprins also contribute to nuclear shape, so 
that mutations in nesprins have been linked to Emery-Dreifuss muscular dystrophy where 
aberrant NE organization is observed (74). Thus, in theory, alteration of the expression of 
nesprins in cancer could lead to changes in cytoskeleton and nuclear stiffness and 
elasticity, nuclear shape, and nuclear size and accordingly enable extravasation of tumor 
cells during metastatic spread. These functions are particularly interesting in that analysis 
of patient sequences in the TCGA cancer database (75) revealed relatively high mutation 
frequencies in this family with mutations in SYNE1 (encoding nesprin 1) reaching 26% in 
Stomach Adenocarcinoma, 24% in Skin Cutaneous Melanoma and 21% in Colon 
Adenocarcinoma. Other nesprins were also highly mutated in specific tumor types with 
SYNE2 (encoding nesprin 2) mutated in 20% of Liver Hepatocellular Carcinoma patients 
and more than 10% in at least four different cancer types. Interestingly, SYNE3 (encoding 
nesprin 3) was only highly mutated in Pancreatic Adenocarcinoma, at 24% of patients, with 
the next highest mutation frequency being at just 3% in Lung Adenocarcinoma, indicating 
considerable tissue-specificity even just amongst this protein family in its potential 
relationship to cancer. Notably, several different cancers had much lower levels of 
mutations in SYNE/nesprin proteins, often as much as 100-fold lower (Fig. 2). 
 Tissue-specific NETs also contribute to these complexes. NET5/Samp1 is not 
detected in most tissues, but has distinct splice variants in brain and muscle (76). NET5 
was found in TAN-lines, nucleo-cytoskeletal connections involved in nuclear migration 
(77). NET5 was also found to be important for associations between the nucleus and the 
centrosome that organizes microtubules (31). 
 
Nuclear Envelope Transmembrane proteins (NETs) 
Both the nesprins and SUN proteins are NETs and, just like these two protein families 
largely segregate between the ONM and INM, so do other NETs. There are now many 
hundreds of NETs that have been identified in the NE by proteomics and most of which 
are tissue-restricted in expression (26,28,36,38), suggesting they might contribute to the 
tumor tissue-type specificity of nuclear size effects in cancer. Over 50 NETs have been 
characterized by super resolution microscopy for their accumulation in the ONM or INM, 
with a strong majority favoring the INM (78). Some ONM NETs, like nesprins, contribute to 
mediation of interactions with cytoplasmic filaments. Others are involved in cell cycle 
regulation, for example NET4/Tmem53 activates a stress-induced p38 kinase pathway that 
results in cell cycle withdrawal when its levels are perturbed (33). Another ONM NET 
affecting the cell cycle, NET31/Tmem209, is able to alter cancer cell growth when 
overexpressed in lung cancer cells and interestingly is up regulated in lung cancer cells 
and normal testis that contains highly proliferative cells (79). As loss of proliferation 
controls is a hallmark of cancer cells, these NETs could also be highly relevant to 
metastatic tumors, though they have thus far not been linked to nuclear size regulation. 
Very little is known about most other ONM NETs.  
 Many INM NETs interact with lamins and chromatin and play important roles in 
gene/chromosome positioning, chromatin organization and epigenetics, and genome 
regulation (34,36,80–82). Though most of general radial chromosome positioning is based 
on gene density (83), each tissue also has a subset of genes and chromosomes that 
reposition during differentiation in a tissue-specific manner (40,41,84,85). The general 
positioning trends appear to be driven by heterochromatin interactions with lamins and the 
NET lamin B receptor (LBR) that binds directly to heterochromatin protein 1 (HP1) (80). In 
general, the periphery tends to be a more silencing environment based on expression 
profiles and epigenetic marks of genome-wide identified genes that reside there (86). The 
more tissue-specific gene and chromosome repositionings are directed by tissue-specific 
NETs. For example, liver NETs NET45/Dak and NET47/TM7SF2 are important for 
positioning to the NE of chromosome 5 in liver cells (76) and muscle NETs 
NET39/PPAPDC3, Tmem38A, and WFS1 are important for positioning to the NE of 
several genes that need to be tightly shut down in a temporal fashion later in muscle 
differentiation though they are needed in earlier stages (36). Interestingly, there are also 
many genes that reposition to the more repressive environment of the NE in tissue 
differentiation that support cell proliferation and must be shut down because most 
differentiated cells no longer cycle (36–38) Thus, alteration of the normal expression 
patterns for such NETs in cancer could support metastasis by increasing expression of 
proliferative genes.  
 Though little is known about most NETs to determine their likelihood of contributing 
to cancer progression or metastasis, analysis of NETs identified in NE proteomic studies 
for changes in different tumour types using the TCGA cancer database (75) revealed that 
many tend to be lost or inappropriately expressed in a variety of tissue-specific tumor 
types. One example is the NET LPCAT3, a protein expressed relatively widely, but not in 
ovary. Its expression profile changes drastically in certain cancer types, with it being 
strongly upregulated in ovarian cancer but down-regulated in lung cancer (3,87). The 
tissue-specific differences characteristic of each tumor type may be explained by such 
changes in these tissue specific NETs during cancer progression.  
 
What advantages can nuclear size changes confer to cancer cells?  
The central conundrum that faces us is how can both nuclear size increases and 
decreases promote increased metastasis in different tumor types? A smaller nuclear size 
could obviously convey the advantage of being able to squeeze through junctions between 
cells during invasion of other tissues, but one might expect that a larger nuclear size would 
hinder this. This apparent contradiction might be resolved when considering that the NE 
connects to both cytoplasmic filaments on one side and chromatin on the other side. The 
largest molecules in the cell are the chromosomes that reach gigadalton masses and 
dwart even actin stress fibers in total size. Several studies have shown that chromatin 
connections to the NE are similarly important as the intermediate filament lamin polymer 
for nuclear shape and mechanical stability (88,89). If the increase in nuclear size is 
associated wjth a reduction of dense chromatin (particularly at the periphery, then the 
strength of heterochromatin interactions with the NE might diminish to enable the even 
larger nucleus to distort and squeeze between cell-cell junctions for invasion (Fig. 3A). It is 
interesting that there is precedent for a third type of change where in neutrophil 
differentiation an increase in NE-chromatin connections and compacted chromatin drives 
formation of a 5-lobed nucleus that resembles sausage links (90). As each lobe/ link is 
very thin, this could also facilitate squeezing through tight junctions. 
 Notably, the neutriphil nuclear lobulation is also driven by changes in nucleo-
cytoskeletal connections associated with increased lamin B2 levels and reduced lamin A 
levels (91). Several studies have shown that lamin A contributes more to nuclear strength 
and stability than other lamin subtypes and in vitro binding assays revealed lamin B2 to 
have the weakest and least stable interactions (46,92). Such connections might provide an 
even simpler explanation if both nuclear size increases and decreases are associated with 
changes in cytoplasmic filament connections that facilitate cell migration. The separate 
findings that altering levels of lamins and LINC components affects cell migration in wound 
healing assays (47) indicates the likelihood of this possibility. Furthermore, tissue-specific 
NETs that contribute to lamin-LINC-cytoplasmic filament connections could confer the 
tumor type specificity for this nexus. Importantly, such disruption of the even larger 
chromatin-lamin-LINC-cytoplasmic filament nexus could additionally weaken the 
mechanical stability of the nucleus to explain the changes in nuclear shape that include 
blebbing at the NE that often accompany nuclear size changes (Fig. 3B). 
 A larger nuclear size accompanied by a reduced heterochromatin interaction with 
the nuclear periphery might also enable faster proliferation for metastasis, not just through 
changes in gene expression or post-translational modifications as mentioned above, but 
also by having less late-replicating peripheral heterochromatin and having to break fewer 
genome-NE contacts when replicating the genome. Changes in such contacts could also 
influence overall genome stability whether due to loss of lamin A or a tissue-specific NET. 
Notably, lamins also bind pRb and can affect proliferation by sequestering or releasing 
pRb (35,93). Similarly, several NETs bind transcriptional regulators and Smads  
are sequestered by the NET MAN1 away from target genes in the nucleoplasm such that 
altering MAN1 can yield bone disorders (94–96). Thus both lamins and tissue-specific 
NETs can influence metastasis through effects on proliferation that could parallel nuclear 
size changes from the same proteins. 
  
 
Conclusions 
It is clear that characteristic nuclear size changes correlate with particular tumor types; 
however, it remains unproven whether these changes are secondary to driver changes in 
the cancers or if they directly influence the cancer progression and metastasis. There are 
many ways noted above that both the size change itself or associated changes in NE-
chromatin or NE-cytoplasmic filament connections can provide advantages to cancer cells. 
These range from migratory aspects of metastasis such as increased cell migration and an 
enhanced ability to squeeze through cell junctions in invading other tissues to an 
increased proliferative capacity and altered gene expression. Despite the obvious logic of 
this, the NE is extremely under-investigated in cancer research and so there are no 
conclusive studies demonstrating a role of nuclear size regulation in promoting cancer 
progression or metastasis. Similarly, there is little data available regarding the three 
mechanisms (limiting, mechanical sensor, post-translational modification) suggested to 
underlie the loss in nuclear size control. That to date the strongest supporting studies have 
all to do with a limiting function most probably only reflects the complexity of NE building 
blocks as the proteins identified with such functions are all widely expressed and most 
nuclear size changes in cancer are specific to a particular tumor type. We postulate that 
many of the tissue-specific NETs will be found to play critical roles in such tumor type 
specific characteristic changes in the karyoplasmic ratio. Due to their tissue-specificity 
such NETs would be fantastic targets for cancer therapies as their specificity should 
reduce toxic side effects in treatment while, being more directly linked to the metastasis, 
they might significantly improve survival of more metastatic tumors. 
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Figure legends 
 
FIG 1 Potential mechanisms of nuclear size regulation. A. Control of levels for scaffolding 
proteins regulating nuclear size. Reduction of scaffolding proteins such as lamins 
through gene misregulation could be limiting for nuclear size increases (left). At the 
same time, upregulation of such proteins could promote nuclear growth (right). B. 
Sensor mechanism regulating the karyoplasmic ratio. The sensor might sense 
alterations of tension between the NE and chromatin and/or the cytoskeleton and 
alter nuclear size accordingly. C. Post-translational modifications occurring on NE 
proteins. Similar to how hyperphosphorylation of lamins triggers their disassembly in 
mitosis, modifying proteins at the NE to break connections could alter nuclear size. 
 
 
 
FIG 2 Alteration of SYNE genes encoding nesprins, members of the LINC complex, in 
different cancer types. Accumulation of mutations in SYNE genes differs for each 
gene and for each tumor type. For example, SYNE3 is only highly mutated in 
Pancreatic Adenocarcinoma while SYNE1 and SYNE2 are highly mutated in a 
larger, but partly distinct, set of cancers. Blca: Bladder Urothelial Carcinoma; Brca: 
Breast Invasive Carcinoma; Coadread: Colon Adenocarcinoma; Gmb: Glioblastoma 
Multiforme; Hnsc: Head and Neck Squamous Cell Carcinoma; Kich: Kidney 
Chromophobe; Kirc: Kidney Renal Clear Cell Carcinoma; Luad: Lung 
Adenocarcinoma; Lusc: Lung Squamous Cell Carcinoma; Ov: Ovarian Serous 
Cystadenocarcinoma; Paad: Pancreatic Adenocarcinoma; Stad: Stomach 
Adenocarcinoma; Thca: Thyroid Carcinoma.   
 
 
 
FIG 3 Advantages to cancer cells of nuclear size changes. A. Smaller nuclei with more 
compact chromatin could more readily squeeze between tight cell-cell junctions to 
invade a tissue (top). If a bigger nucleus has fewer interactions with chromatin 
and/or more euchromatin, this might enable greater malleability for the nucleus to 
change shape to squeeze between cell-cell junctions (bottom). B. Alterations of 
lamin and LINC complex connections. Loss of lamins can weaken the mechanical 
properties of the nucleus, allowing easier deformability in squeezing through cell-
cell junctions and so increasing metastasis (upper panels). The connections 
between the nucleoskeleton and cytoplasmic filaments also affect cell migration in 
wound healing assays and so their disruption could result in an increased speed for 
migration of the cancer cell (bottom panels). Note that in this case both changes to 
larger and smaller nuclear size could alter nuclear migration properties. 
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